Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
NVS Novartis AG daily Stock Chart
Novartis AG
Index- P/E23.61 EPS (ttm)3.95 Insider Own- Shs Outstand2.75B Perf Week2.15%
Market Cap256.20B Forward P/E17.16 EPS next Y5.44 Insider Trans- Shs Float415.24M Perf Month-2.44%
Income9.70B PEG3.33 EPS next Q1.34 Inst Own9.90% Short Float0.82% Perf Quarter-5.42%
Sales51.75B P/S4.95 EPS this Y16.20% Inst Trans0.19% Short Ratio1.81 Perf Half Y-6.96%
Book/sh32.60 P/B2.86 EPS next Y5.82% ROA15.00% Target Price113.50 Perf Year3.08%
Cash/sh2.11 P/C44.11 EPS next 5Y7.10% ROE26.30% 52W Range81.85 - 106.84 Perf YTD3.51%
Dividend2.67 P/FCF71.25 EPS past 5Y3.20% ROI10.50% 52W High-12.70% Beta0.66
Dividend %2.86% Quick Ratio0.60 Sales past 5Y3.50% Gross Margin66.60% 52W Low13.95% ATR2.01
Employees120000 Current Ratio0.80 Sales Q/Q-52.20% Oper. Margin21.40% RSI (14)43.51 Volatility2.10% 1.69%
OptionableYes Debt/Eq0.30 EPS Q/Q-63.50% Profit Margin37.80% Rel Volume0.79 Prev Close91.90
ShortableYes LT Debt/Eq0.17 EarningsOct 27 BMO Payout34.00% Avg Volume1.89M Price93.27
Recom1.80 SMA20-1.12% SMA50-5.08% SMA200-5.94% Volume1,499,306 Change1.49%
Jun-22-15Upgrade Bryan Garnier Neutral → Buy
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-26-09Initiated Jefferies & Co Hold
Sep-23-08Upgrade Credit Suisse Underperform → Neutral
Aug-06-08Downgrade JP Morgan Overweight → Neutral
Jun-12-08Downgrade HSBC Securities Neutral → Underweight $52 → $49
Jun-04-08Upgrade Cowen & Co Neutral → Outperform
May-09-08Upgrade Bernstein Mkt Perform → Outperform
Apr-08-08Downgrade Bear Stearns Outperform → Peer Perform
Feb-29-08Initiated Cowen & Co Neutral
Feb-29-08Downgrade HSBC Securities Neutral → Underweight
Sep-06-07Initiated UBS Buy
Jul-18-07Downgrade Credit Suisse Neutral → Underperform
Jun-01-07Reiterated Prudential Overweight $64 → $62
Oct-02-15 06:21PM  XOMA Shoots up on Immuno-Oncology Deal with Novartis
12:03PM  Amgen Is In Novartis' Crosshair at Motley Fool
03:31AM  Novartis biosimilar copycat takes aim at Amgen's drug Enbrel Reuters
Oct-01-15 07:02PM  Working in-house becomes an exciting option for lawyers at Financial Times
07:02PM  Law firms implement tactics to level the playing field at Financial Times
05:50PM  Novartis Announces Positive Data on Arthritis Drug Cosentyx
07:46AM  Xoma enters exclusive license agreement with Novartis at MarketWatch
Sep-30-15 08:34AM  Novartis CEO: Here's How We'll Get Cheap Medicine To Poor Countries at Forbes
Sep-28-15 11:48AM  Roche Drug Scores A Hit Against Stubborn Form Of MS at Investor's Business Daily
09:30AM  Delta Air Lines, Tribune Publishing, Aduro BioTech, Incyte and Novartis highlighted as Zacks Bull and Bear of the Day
Sep-26-15 09:00AM  In A First, Kidney Cancer Drug Extends Survival at Forbes
Sep-25-15 06:02PM  Bristol, Exelixis Drugs Demonstrate Treatment Benefit in Kidney Cancer at TheStreet
06:01PM  Bristol-Myers Kidney Cancer Drug Boosts Survival in Big Study at Bloomberg
10:00AM  Shire's (SHPG) Vyvanse U.S. Patent Validated, Expiry in 2023
09:07AM  Industrials Save Ivy European Opportunities Fund in August 2015
06:29AM  Novartis' new heart drug on track for approval in Europe Reuters
Sep-24-15 02:14PM  Pharmaceuticals: Value over volume at Financial Times
12:20PM  What You Should Know about the T. Rowe Price European Stock Fund
Sep-23-15 05:44PM  Amgen, Allergan Biosimilar Avastin Hits In Trial at Investor's Business Daily
03:47PM  European Stocks Fall due to Declining Consumer Confidence
03:06PM  Did Genzyme Drive Sanofis Growth in 2Q15?
01:21PM  Under HIllary Clinton, Generic Drugmakers Could Soar at Motley Fool
Sep-22-15 04:51PM  Pfizer says it could be leader in cancer with many new drugs
05:04AM  UK pushes to be Chinas best partner despite fears at CNBC
Sep-21-15 04:35PM  What Was the Market Response to Sanofis 2Q15 Earnings?
07:59AM  Roche scion André Hoffman on benefits of family ownership at Financial Times
Sep-18-15 05:16PM  Alexandria Real Estate Equities, Inc. -- Moody's affirms Alexandria's Baa2 rating; stable outlook at Moody's
10:32AM  Roche shows its intent with Switzerland's tallest skyscraper Reuters
08:49AM  Novartis will weather the EM market storm: CEO at CNBC
Sep-17-15 08:00AM  How the U.S. could cure drug-price insanity at Fortune
Sep-16-15 01:51PM  Amgen buys 1 company, partners with 2nd to create new drugs
01:30PM  The Safest Stock To Own In Any Market
10:14AM  Amgen to Buy Dezima, Signs Pact With Xencor at The Wall Street Journal
Sep-15-15 02:29PM  NIMH director to leave for Google Life Sciences Reuters
12:05PM  Philips to spin off lighting arm and step up medical tech drive at Financial Times
Sep-14-15 09:42AM  Is The Superiority Of Entresto Just An Illusion? at Forbes
Sep-11-15 10:41PM  New Novartis Heart-Failure Drug Should Cost 17% Less, Research Group Says at The Wall Street Journal
03:51PM  Novartis Heart Drug Overpriced, Group Says at The Wall Street Journal
01:09PM  Lifesaving blood pressure study
12:35PM  Biogen: 'We Continue to Aggressively Recommend Purchase' at
Sep-10-15 04:31PM  First 'biosimilar' of a biologic drug reaches US, finally
11:45AM  Enrollment balloons in WPIs new drug manufacturing program at
08:30AM  Why the Swiss Franc Is the Golden Currency
Sep-09-15 01:29PM  Attention Biotech Investors: Biosimilars Are Finally Here! at Motley Fool
09:24AM  Biogen Takes on Celgene With New Autoimmune License Deal at TheStreet
Sep-08-15 10:24AM  Research and Markets: Investigation Report on China's Letrozole Market 2010-2019 Business Wire
08:06AM  Merck: Other Human Health Franchise and Animal Health Segment
Sep-07-15 12:07PM  Whats the Market Response to Repathas Approval?
10:50AM  Novartis' Farydak Gets EU Approval for Multiple Myeloma
Sep-06-15 08:02AM  You Don't Have to Wait for the Next Big Thing in Biotech -- It's Already Here at Motley Fool
Sep-05-15 05:11PM  Novartis to start human tests with Google lens in 2016
Sep-04-15 03:07PM  Repathas Clinical Profile Is Superior to Existing Statin Therapies
12:51PM  Amgen Biosimilar Rival Delayed After Zarxio Launch at Investor's Business Daily
11:21AM  Amgen: Time is on My Side at
09:01AM  Merck: Analyzing the Companys Growth Rate
05:34AM  Research and Markets: Investigation Report on China's Octreotide Market, 2010-2019 Business Wire
12:21AM  Big Pharma: The Moment of Dread Is Here at The Wall Street Journal
Sep-03-15 03:15PM  Novartis (NVS) Launches Zarxio: First Biosimilar in the U.S.
03:10PM  Big Pharma: The Moment of Dread Is Here at The Wall Street Journal
03:03PM  Amgen (AMGN) Stock Falls as Novartis Begins Selling Biosimilar Version of Neupogen at TheStreet
02:59PM  First biosimilar hits US
12:41PM  Novartis to Begin Selling Copy of Amgen's Neupogen in U.S. at The Wall Street Journal
09:09AM  Research and Markets: Investigation Report on China's Imatinib Mesylate (Novartis) Market 2010-2019 Business Wire
08:12AM  Novartis launches first U.S. 'biosimilar' drug at 15 pct discount Reuters
08:02AM  The Next Blockbusters Could Be Balms For Aging Eyes at Investor's Business Daily
08:02AM  Regeneron, Roche, Bayer, More Set Sights On Better Eye Drugs
07:36AM  Novartis launches first biological copycat drug in US at Financial Times
06:51AM  First Biosimilar Drug Goes on Sale in U.S., Challenging Amgen at Bloomberg
01:30AM  Novartis launches Neupogen copycat Zarxio in U.S. market
Sep-02-15 04:50PM  Amgen, Novartis Team Up; Bone Drug Positive in Phase III
04:28PM  Another Cambridge gene-editing startup raises millions in funding at
04:09PM  Amgen cannot stop imminent sale of Neupogen copycat -U.S. appeals court Reuters
04:05PM  Novartis Closer to Selling Copy of Amgen's Neupogen at The Wall Street Journal
03:03PM  Some leukemia patients see durable results from Novartis therapy
02:55PM  Can Amgen Withstand Biosimilars?
12:35PM  Amgen: Good News Comes in Twos at
11:42AM  Amgen cannot stop imminent sale of Neupogen copycat: U.S. appeals court Reuters
10:38AM  Amgen, Novartis Alzheimer's Deal Gets Cautious Praise at Investor's Business Daily
07:05AM  Sept. 2 Premarket Briefing: 10 Things You Should Know
04:45AM  Novartis, Amgen partner on Alzheimer's, migraine treatment
12:31AM  Business Watch at The Wall Street Journal
Sep-01-15 09:02PM  Amgen and Novartis partnering on a drug that could prevent Alzheimer's at Los Angeles Times
05:34PM  Valeant steps in to work on psoriasis drug with AstraZeneca
05:18PM  Amgen to Help Develop Novartis's Pipeline of Alzheimer's Drugs at The Wall Street Journal
10:50AM  Valeant Buys Abandoned AstraZeneca Psoriasis Drug at Investor's Business Daily
Aug-31-15 07:55PM  How Google looks to change the management of diabetes at
Aug-28-15 05:15PM  Lucky 7: These Stock Market Leaders Have Top Dividend Growth Rates at Investor's Business Daily
02:32PM  Swiss Miss: Switzerland Skirts Recession, But ETFs Struggle
09:36AM  Research and Markets: Investigation Report on China's Ranibizumab Market, 2012-2019 Business Wire
Aug-27-15 10:46AM  Things could get pricey if you wear contacts
08:00AM  Contact lens makers see their day in court
Aug-26-15 04:52PM  Getting a flu shot? There are new options
04:45PM  Novartis' (NVS) Promacta Label Further Expanded in U.S.
01:53PM  Glaxo in $1 Billion Ofatumumab Deal With Novartis at Investopedia
08:44AM  GlaxoSmithKline Lines Its Pockets Courtesy of Novartis Once Again at Motley Fool
Aug-24-15 03:04PM  FDA Grants Expanded Use of Promacta for Novartis
Aug-21-15 01:05PM  Novartis could pay more than $1B for GlaxoSmithKline MS drug
12:40PM  Novartis' Odomzo Gets European Approval for Skin Cancer
06:39AM  European Stocks Fall Further as Volatility Outweighs Strong Economic Data at TheStreet
03:30AM  European stocks plunge on China, Greece worries at CNBC
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company's Alcon division provides various eye care products, including surgical, ophthalmic pharmaceuticals, and vision care products; ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers generic pharmaceuticals comprising active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or biotechnology-based products; and cytotoxic products for the hospital market, as well as biotech manufacturing services to other companies. The company distributes its OTC products through various channels, such as pharmacies, food, drug, and mass retail outlets. Novartis AG has collaboration with Amgen Inc. in the areas of Alzheimer's disease and migraine. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.